Genentech and Gilead will lead the pack with 25 percent CAGR. According to Wood Mackenzie, the premier provider of global life sciences information, the growth of the biotechnology industry will continue to outpace that of pharmaceutical companies, with the seven largest biotechnology companies growing at rates faster than the pharmaceutical industry's 9.1 per cent average.

Biotechnology's big arrival is one of several key trends analyzed in Wood Mackenzie's 2004 Executive's Guide. The analysis shows that Amgen is now ranked among the top 20 global pharmaceutical companies in the world and will break into the top 10 by 2008. In addition, the report notes that five of the 10 largest mergers and acquisitions in 2003 were within the biotechnology sector - indicating continued growth and maturity.

"Our research shows what the industry has suspected: biotechnology companies have truly come into their own," said Wood Mackenzie Life Sciences President Jim Hall. "As biotechs increasingly retain ownership of their developmental compounds and create more targeted blockbuster drugs, they will grow faster than pharmaceutical companies."

Wood Mackenzie's 2004 Executive's Guide combines high-level analysis with in-depth statistics on the 50 top-ranking pharmaceutical and biotechnology companies. Highlights of the guide include profiles of the top 50 global pharmaceutical and biotechnology companies, executive overviews of the biotechnology and pharmaceutical markets, an executive overview of key therapy areas, and a rankings table of the top 50 pharmaceutical companies.

Genentech and Gilead will lead the pack with 25% CAGR

According to Wood Mackenzie, the premier provider of global life sciences information, the growth of the biotechnology industry will continue to outpace that of pharmaceutical companies, with the seven largest biotechnology companies growing at rates faster than the pharmaceutical industry's 9.1 percent average.

Biotechnology's big arrival is one of several key trends analyzed in Wood Mackenzie's 2004 Executive's Guide. The analysis shows that Amgen is now ranked among the top 20 global pharmaceutical companies in the world and will break into the top 10 by 2008. In addition, the report notes that five of the 10 largest mergers and acquisitions in 2003 were within the biotechnology sector - indicating continued growth and maturity.

- Business Wire